Tiger Brokers

US StockDetailed Quotes
Provided by Tiger Trade Technology Pte. Ltd.

Tema Heart & Health ETF

35.80
-0.0478-0.13%
Post-market: 35.68-0.1239-0.35%19:30 EDT
Volume:1K
Turnover:45.58K
Market Cap:52.99M
PE:- -
High:35.80
Open:35.68
Low:35.68
Close:35.85
52wk High:38.87
52wk Low:31.87
Shares:1.48M
Float Shares:1.48M
Volume Ratio:0.73
T/O Rate:0.09%
Dividend:0.47
Dividend Rate:1.32%
ROE:--
ROA:--
PB:--
PE(LYR):- -

Loading ...

OverviewCompanyNewsFilings

FDA approves Welireg and Lenvima combo for ccRCC

TIPRANKS
·
Sep 25

Merck Shares Flat in Volume Spike After FDA Approves Kidney Drug, Last up 0.50% at $148.81

THOMSON REUTERS
·
Sep 25

FDA Approves Belzutifan in Combination with Lenvatinib for Advanced Renal Cell Carcinoma with a Clear Cell Component

THOMSON REUTERS
·
Sep 25

Merck Has Two Overlooked Pipeline Catalysts Coming Before Year-End, UBS Says

MT Newswires Live
·
Sep 25

S&P 500 Top and Bottom Performing Stocks at About 12:00 P.m. EDT

Reuters
·
Sep 25

Eli Lilly and Co Stock (LLY) Moved Up by 3.73% on Sep 24: A Full Analysis

TradingKey
·
Sep 24

Thermo Fisher Scientific on Track for Record High Close

Dow Jones
·
Sep 24

Lilly's Next-Gen Obesity Efforts Could Tip Scales Further in Its Favor, Citi Says

Reuters
·
Sep 24

UnitedHealth Adds Jodee Kozlak as Chief Administrative Officer Effective Sept. 28, 2026

Reuters
·
Sep 24

UnitedHealth Group Announces Addition to Leadership Team

THOMSON REUTERS
·
Sep 24

UnitedHealth - Appoints Jodee Kozlak as Chief Administrative Officer Effective Sept. 28, 2026

THOMSON REUTERS
·
Sep 24

Merck's Drug for Diabetes-Related Eye Disease Meets Trial Goal

Reuters
·
Sep 24

Eli Lilly Gets FDA OK for Onswik Once-Weekly Insulin Injection

Dow Jones
·
Sep 24

Merck Says Remigromig Meets Primary Endpoint in Pivotal Brunello Trial for Diabetic Macular Edema

Reuters
·
Sep 24

Eli Lilly - Onswik Kwikpen to be Available in U.S. in 500 Units/Ml and 1,000 Units/Ml Concentrations

THOMSON REUTERS
·
Sep 24

U.S. Food and Drug Administration (FDA) Approves Lilly's Onswik™ (Insulin Efsitora Alfa-Gobe), a Once-Weekly Basal Insulin Injection Treatment for Adults Living with Type 2 Diabetes

THOMSON REUTERS
·
Sep 24

Merck & Co - Higher Rates of Pdr, Vitreous Hemorrhage, and Discontinuations with Remigromig

THOMSON REUTERS
·
Sep 24

Merck’s Remigromig, a Tri-Specific Agonist of the Wingless-Related Integration Site (Wnt) Pathway, Met Primary Endpoint in the Pivotal Phase 2B/3 Brunello Study of Adults with Diabetic Macular Edema

THOMSON REUTERS
·
Sep 24

Merck & Co Inc: Both Doses of Remigromig were Generally Well Tolerated

THOMSON REUTERS
·
Sep 24

Merck & Co - Both Remigromig Doses Show Non-Inferiority to Ranibizumab at 52 Weeks

THOMSON REUTERS
·
Sep 24
More